Literature DB >> 4002198

Inhibition of low molecular weight heparin by protamine chloride in vivo.

J Harenberg, A Gnasso, J X de Vries, R Zimmermann, J Augustin.   

Abstract

To determine the antagonization of anticoagulant and lipolytic effects of a low molecular weight [LMW] heparin preparation protamine chloride was given intravenously after i.v. injection of LMW or normal heparin. The effects of normal heparin on factor Xa, thrombin, aPTT, lipoprotein [LPL] and hepatic triglyceride lipase [HTGL] activities were neutralized immediately by i.v. protamine. The inhibition of thrombin and aPTT by LMW heparin were also abolished, whereas the effects on LPL and HTGL were counteracted to 80% and on factor Xa only to 40% by i.v. protamine chloride. No rebound of the anticoagulant or lipolytic effect was detected. It is assumed that haemorrhagic complication during therapy can be antagonized by protamine chloride. The incomplete inhibitory effect of protamine chloride on LPL, HTGL and factor Xa activities of LMW heparin indicate that protamine chloride requires more than 14 saccharide units in the heparin molecule for interaction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4002198     DOI: 10.1016/0049-3848(85)90003-9

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

2.  [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].

Authors:  J Harenberg; C Giese; A Knödler; R Zimmermann; G Schettler
Journal:  Klin Wochenschr       Date:  1986-11-17

3.  A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with acenocoumarol) in patients undergoing gynaecological surgery.

Authors:  R A Steiner; K Keller; T Lüscher; W E Schreiner
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

4.  Treatment of acute subdural hematoma.

Authors:  Carter Gerard; Katharina M Busl
Journal:  Curr Treat Options Neurol       Date:  2014-01       Impact factor: 3.598

Review 5.  Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.

Authors:  H A Friedel; J A Balfour
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

6.  Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins.

Authors:  Ahmed Kouta; Walter Jeske; Debra Hoppensteadt; Omer Iqbal; Yiming Yao; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.